Payment overview · 2025
General Payments
$1,070.33
49 reported records · 15 companies
Healthcare provider profile · identity verified
Kamyar Kamjoo, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · TARZANA, CA · NPI 1558465708
Verified facts
What the public records show
CMS Open Payments records show Kamyar Kamjoo, MD received $1,070.33 in general payments during 2025 across 49 reported records.
Amgen Inc. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $271.57 | 25.4% | 17 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $151.12 | 14.1% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $140.64 | 13.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $119.66 | 11.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $80.80 | 7.5% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $72.89 | 6.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.03 | 4.3% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $37.54 | 3.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $30.36 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.76 | 2.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $22.77 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.95 | 2.0% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $17.44 | 1.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.53 | 1.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.27 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,070.33 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $151.12 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $119.66 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $86.59 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $85.63 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $77.22 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $72.89 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $72.43 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $65.98 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $50.79 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.79 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $50.79 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $47.53 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.03 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $37.54 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $30.36 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.01 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.01 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 61 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 154 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
99 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
117 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 709 | 183 |
| Levothyroxine Sodium | Levothyroxine Sodium | 365 | 97 |
| Losartan Potassium | Losartan Potassium | 359 | 98 |
| Nifedipine Er | Nifedipine | 251 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 228 | 69 |
| Allopurinol | Allopurinol | 224 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 219 | 55 |
| Repatha Sureclick | Evolocumab | 205 | 34 |
| Furosemide | Furosemide | 193 | 50 |
| Trazodone Hcl | Trazodone Hcl | 182 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 169 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 58 |
| Jardiance | Empagliflozin | 154 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 35 |
| Alendronate Sodium | Alendronate Sodium | 147 | 44 |
| Gabapentin | Gabapentin | 143 | 36 |
| Metformin Hcl | Metformin Hcl | 137 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 39 |
| Lisinopril | Lisinopril | 132 | 34 |
| Eliquis | Apixaban | 117 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 26 |
| Simvastatin | Simvastatin | 102 | 31 |
| Mounjaro | Tirzepatide | 99 | 13 |
| Alprazolam | Alprazolam | 97 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 45 |
| Azithromycin | Azithromycin | 88 | 77 |
| Carvedilol | Carvedilol | 87 | 16 |
| Omeprazole | Omeprazole | 85 | 21 |
| Tramadol Hcl | Tramadol Hcl | 73 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 18 |
| Lorazepam | Lorazepam | 72 | 25 |
| Montelukast Sodium | Montelukast Sodium | 68 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 22 |
| Famotidine | Famotidine | 64 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 18 |
| Bumetanide | Bumetanide | 61 | 14 |
| Farxiga | Dapagliflozin Propanediol | 61 | 15 |
| Bupropion Xl | Bupropion Hcl | 60 | 12 |
| Metformin Hcl Er | Metformin Hcl | 59 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 11 |
| Temazepam | Temazepam | 56 | suppressed |
| Lactulose | Lactulose | 53 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 39 |
| Finasteride | Finasteride | 51 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 13 |
| Sertraline Hcl | Sertraline Hcl | 51 | 14 |
| Valsartan | Valsartan | 51 | 17 |
| Synthroid | Levothyroxine Sodium | 50 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 15 |
| Potassium Chloride | Potassium Chloride | 45 | 14 |
| Ezetimibe | Ezetimibe | 43 | suppressed |
| Linzess | Linaclotide | 43 | suppressed |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | 12 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Praluent Pen | Alirocumab | 38 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 36 | 17 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | suppressed |
| Clonazepam | Clonazepam | 34 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 16 |
| Prednisone | Prednisone | 34 | 18 |
| Levofloxacin | Levofloxacin | 33 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Calcium Acetate | Calcium Acetate | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 18 |
| Acyclovir | Acyclovir | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Creon | Lipase/Protease/Amylase | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Nystatin | Nystatin | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 27 |
| Sodium Chloride | Sodium Chloride 0.45 % | 28 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Estradiol | Estradiol | 25 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 18 |
| Pregabalin | Pregabalin | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Minoxidil | Minoxidil | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Multaq | Dronedarone Hcl | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Procrit | Epoetin Alfa | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Bystolic | Nebivolol Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | 13 |
| Nitroglycerin Patch | Nitroglycerin | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,070.33 · 49 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FUROSCIX, Fluad, Flucelvax, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, Leqembi, NEXLETOL, NURTEC ODT, Ozempic, PREVNAR 20, REPATHA, SHINGRIX, TAVNEOS, TZIELD, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error